WuXi AppTec Co Ltd (603259) - Total Liabilities

Latest as of June 2025: CN¥23.41 Billion CNY ≈ $3.43 Billion USD

Based on the latest financial reports, WuXi AppTec Co Ltd (603259) has total liabilities worth CN¥23.41 Billion CNY (≈ $3.43 Billion USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

WuXi AppTec Co Ltd - Total Liabilities Trend (2014–2024)

This chart illustrates how WuXi AppTec Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See how liquid is WuXi AppTec Co Ltd's working capital to evaluate short-term liquidity relative to the company's equity base.

WuXi AppTec Co Ltd Competitors by Total Liabilities

The table below lists competitors of WuXi AppTec Co Ltd ranked by their total liabilities.

Company Country Total Liabilities
Keysight Technologies Inc
NYSE:KEYS
USA $5.42 Billion
Naspers Limited
JSE:NPN
South Africa ZAC24.55 Billion
China Hongqiao Group Ltd
F:H0Q
Germany €103.67 Billion
WEC Energy Group Inc
NYSE:WEC
USA $37.16 Billion
Nucor Corp
NYSE:NUE
USA $12.85 Billion
PG&E Corp
NYSE:PCG
USA $108.45 Billion
UltraTech Cement Limited
NSE:ULTRACEMCO
India Rs613.38 Billion
Asia Vital Components Co Ltd
TW:3017
Taiwan NT$108.94 Billion

Liability Composition Analysis (2014–2024)

This chart breaks down WuXi AppTec Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 603259 market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.08 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.39 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.28 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how WuXi AppTec Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for WuXi AppTec Co Ltd (2014–2024)

The table below shows the annual total liabilities of WuXi AppTec Co Ltd from 2014 to 2024.

Year Total Liabilities Change
2024-12-31 CN¥21.24 Billion
≈ $3.11 Billion
+17.01%
2023-12-31 CN¥18.15 Billion
≈ $2.66 Billion
+2.19%
2022-12-31 CN¥17.76 Billion
≈ $2.60 Billion
+8.51%
2021-12-31 CN¥16.37 Billion
≈ $2.40 Billion
+20.61%
2020-12-31 CN¥13.57 Billion
≈ $1.99 Billion
+14.74%
2019-12-31 CN¥11.83 Billion
≈ $1.73 Billion
+162.76%
2018-12-31 CN¥4.50 Billion
≈ $658.78 Million
-22.94%
2017-12-31 CN¥5.84 Billion
≈ $854.93 Million
+29.02%
2016-12-31 CN¥4.53 Billion
≈ $662.63 Million
+39.06%
2015-12-31 CN¥3.26 Billion
≈ $476.50 Million
+22.44%
2014-12-31 CN¥2.66 Billion
≈ $389.18 Million
--

About WuXi AppTec Co Ltd

SHG:603259 China Diagnostics & Research
Market Cap
$35.78 Billion
CN¥244.48 Billion CNY
Market Cap Rank
#761 Global
#50 in China
Share Price
CN¥98.85
Change (1 day)
-0.90%
52-Week Range
CN¥64.00 - CN¥112.85
All Time High
CN¥165.00
About

WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manuf… Read more